riluzole
E133687
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
All labels observed (1)
| Label | Occurrences |
|---|---|
| riluzole canonical | 5 |
How this entity was disambiguated
This entity first appeared as the object of triple T1169549 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: riluzole Context triple: [ALS, hasTreatment, riluzole]
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
C.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
-
D.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
E.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: riluzole Target entity description: Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
A.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
C.
memantine
Memantine is a medication that helps manage symptoms of moderate to severe Alzheimer's disease by modulating glutamate activity in the brain.
-
D.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
E.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
benzothiazole derivative
ⓘ
glutamate release inhibitor ⓘ neuroprotective agent ⓘ pharmaceutical drug ⓘ |
| actsOnDisease | amyotrophic lateral sclerosis ⓘ |
| belongsToPharmacologicalClass | other nervous system drugs ⓘ |
| crosses | blood–brain barrier ⓘ |
| hasATCCode | N07XX02 ⓘ |
| hasBioavailability | about 60 percent ⓘ |
| hasBlackBoxWarning | risk of liver injury ⓘ |
| hasBrandName |
Rilutek
ⓘ
Teglutik ⓘ Tiglutik ⓘ |
| hasCASNumber | 1744-22-5 ⓘ |
| hasChemicalFormula | C8H5F3N2OS ⓘ |
| hasCommonSideEffect |
dizziness
ⓘ
elevated liver enzymes ⓘ nausea ⓘ weakness ⓘ |
| hasDosageForm |
oral suspension
ⓘ
oral tablet ⓘ |
| hasEffect |
modest prolongation of survival in ALS
ⓘ
slowing of disease progression in ALS ⓘ |
| hasEliminationHalfLife | 9 to 15 hours ⓘ |
| hasFDAApprovalYear | 1995 ⓘ |
| hasIUPACName | 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine ⓘ |
| hasLegalStatusInEuropeanUnion | prescription only ⓘ |
| hasLegalStatusInUnitedStates | prescription only ⓘ |
| hasMechanismOfAction |
inactivation of voltage-dependent sodium channels
ⓘ
inhibition of glutamate release ⓘ interference with intracellular events following excitatory amino acid receptor activation ⓘ |
| hasMolarMass | 234.20 g/mol ⓘ |
| hasPregnancyCategoryUS | C ⓘ |
| hasPrimaryMetabolismSite | liver ⓘ |
| hasProteinBinding | about 96 percent ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect | hepatotoxicity ⓘ |
| hasUsualAdultDoseForALS | 50 mg twice daily ⓘ |
| isAdministeredTo | adults with ALS ⓘ |
| isCentrallyActing | true ⓘ |
| isContraindicatedIn | severe hepatic impairment ⓘ |
| isExcretedVia |
feces
ⓘ
urine ⓘ |
| isMetabolizedBy | CYP1A2 ⓘ |
| isNeuroprotective | true ⓘ |
| requiresMonitoringOf | liver function tests ⓘ |
| treats | amyotrophic lateral sclerosis ⓘ |
| wasApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: riluzole Description of subject: Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.